Regeneron Pharmaceuticals (REGN) Debt/Equity Ratio: History & Chart

Regeneron Pharmaceuticals, Inc. (REGN)REGNRegeneron Pharmaceuticals, Inc.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Tarrytown, NY

15,410 employees

www.regeneron.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Leonard S. Schleifer

View full financials

REGN Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.09

DEBT TO EQUITY RATIO AVG TTM

0.09

DEBT TO EQUITY RATIO AVG 3Y

0.10

DEBT TO EQUITY RATIO AVG 5Y

0.11

DEBT TO EQUITY RATIO AVG 10Y

0.10

DEBT TO EQUITY RATIO AVG 15Y

0.15

DEBT TO EQUITY RATIO AVG 20Y

0.18

CURRENT VS TTM AVG

-2.68%

CURRENT VS 3Y AVG

-11.35%

CURRENT VS 5Y AVG

-23.54%

CURRENT VS 10Y AVG

-17.22%

CURRENT VS 15Y AVG

-44.00%

CURRENT VS 20Y AVG

-52.64%

SECTOR MEDIAN · HEALTHCARE

0.67

median of 79 covered companies

CURRENT VS SECTOR MEDIAN

-87.15%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Regeneron Pharmaceuticals, Inc. (REGN)	$67.58B	0.09	0.09	0.10	0.11
Boston Scientific Corporation (BSX)vs ›	$65.77B	0.51	0.51	0.51	0.54
Cencora, Inc. (COR)vs ›	$60.29B	7.13	8.71	10.16	17.42
Cigna Corporation (CI)vs ›	$76.60B	0.75	0.77	0.73	0.72
Becton, Dickinson and Company (BDX)vs ›	$56.65B	0.76	0.79	0.73	0.74
Cardinal Health, Inc. (CAH)vs ›	$53.41B	-3.36	3.77	2.58	2.11
Elevance Health Inc. (ELV)vs ›	$81.91B	0.76	0.78	0.74	0.71
HCA Healthcare, Inc. (HCA)vs ›	$84.78B	-8.33	57.79	57.79	57.79
Edwards Lifesciences Corporation (EW)vs ›	$47.58B	0.07	0.07	0.09	0.11
Humana Inc. (HUM)vs ›	$46.74B	0.73	0.74	0.75	0.72

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Regeneron Pharmaceuticals, Inc. (REGN)

$67.58B

0.09

0.10

0.11

Boston Scientific Corporation (BSX)vs ›

$65.77B

0.51

0.54

Cencora, Inc. (COR)vs ›

$60.29B

7.13

8.71

10.16

17.42

Cigna Corporation (CI)vs ›

$76.60B

0.75

0.77

0.73

0.72

Becton, Dickinson and Company (BDX)vs ›

$56.65B

0.76

0.79

0.73

0.74

Cardinal Health, Inc. (CAH)vs ›

$53.41B

-3.36

3.77

2.58

2.11

Elevance Health Inc. (ELV)vs ›

$81.91B

0.76

0.78

0.74

0.71

HCA Healthcare, Inc. (HCA)vs ›

$84.78B

-8.33

57.79

Edwards Lifesciences Corporation (EW)vs ›

$47.58B

0.07

0.09

0.11

Humana Inc. (HUM)vs ›

$46.74B

0.73

0.74

0.75

0.72

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

The debt to equity ratio for REGN stock is 0.09.

Is Regeneron Pharmaceuticals, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.09 is 27% below its 5-year average of 0.12, near the low end of its 5-year range (0.09–0.23).

What is the TTM average debt to equity ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

The TTM average debt to equity ratio for REGN stock is 0.09.

What is the 3Y average debt to equity ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

The 3Y average debt to equity ratio for REGN stock is 0.10.

What is the 5Y average debt to equity ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

The 5Y average debt to equity ratio for REGN stock is 0.11.

What is the 10Y average debt to equity ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

The 10Y average debt to equity ratio for REGN stock is 0.10.

What is the 15Y average debt to equity ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

The 15Y average debt to equity ratio for REGN stock is 0.15.

What is the 20Y average debt to equity ratio for Regeneron Pharmaceuticals, Inc. (REGN)?

The 20Y average debt to equity ratio for REGN stock is 0.18.

DATE	DEBT TO EQUITY RATIO
2026-03-31	0.09
2025-12-31	0.09
2025-09-30	0.09
2025-06-30	0.09
2025-03-31	0.09
2024-12-31	0.09
2024-09-30	0.09
2024-06-30	0.10
2024-03-31	0.10
2023-12-31	0.10
2023-09-30	0.11
2023-06-30	0.11
2023-03-31	0.11
2022-12-31	0.12
2022-09-30	0.13
2022-06-30	0.13
2022-03-31	0.14
2021-12-31	0.14
2021-09-30	0.16
2021-06-30	0.18
2021-03-31	0.23
2020-12-31	0.24
2020-09-30	0.27
2020-06-30	0.24
2020-03-31	0.06
2019-12-31	0.06
2019-09-30	0.07
2019-06-30	0.07
2019-03-31	0.08
2018-12-31	0.08
2018-09-30	0.09
2018-06-30	0.10
2018-03-31	0.11
2017-12-31	0.11
2017-09-30	0.12
2017-06-30	0.13
2017-03-31	0.15
2016-12-31	0.11
2016-09-30	0.09
2016-06-30	0.09
2016-03-31	0.10
2015-12-31	0.10
2015-09-30	0.12
2015-06-30	0.12
2015-03-31	0.16
2014-12-31	0.18
2014-09-30	0.22
2014-06-30	0.22
2014-03-31	0.24
2013-12-31	0.26
2013-09-30	0.29
2013-06-30	0.32
2013-03-31	0.33
2012-12-31	0.37
2012-09-30	0.56
2012-06-30	0.75
2012-03-31	0.87
2011-12-31	0.90
2011-09-30	0.37
2011-06-30	0.34
2011-03-31	0.31
2010-12-31	0.30
2010-09-30	0.46
2010-06-30	0.43
2010-03-31	0.41
2009-12-31	0.27
2009-09-30	0.15
2009-06-30	0.15
2009-03-31	0.00
2008-12-31	0.01
2008-09-30	0.27
2008-06-30	0.26
2008-03-31	0.43
2007-12-31	0.44
2007-09-30	1.32
2007-06-30	1.12
2007-03-31	1.02
2006-12-31	0.92
2006-09-30	3.20
2006-06-30	2.39
2006-03-31	1.95
2005-12-31	1.75
2005-09-30	1.47
2005-06-30	1.21
2005-03-31	1.08
2004-12-31	1.10
2004-09-30	1.12
2004-06-30	1.05
2004-03-31	0.98
2003-12-31	1.55
2003-09-30	1.34
2003-06-30	1.49
2003-03-31	1.21
2002-12-31	1.37
2002-09-30	1.11
2002-06-30	0.94

DATE

DEBT TO EQUITY RATIO

2026-03-31

0.09

2025-12-31

0.09

2025-09-30

0.09

2025-06-30

0.09

2025-03-31

0.09

2024-12-31

0.09

2024-09-30

0.09

2024-06-30

0.10

2024-03-31

0.10

2023-12-31

0.10

2023-09-30

0.11

2023-06-30

0.11

2023-03-31

0.11

2022-12-31

0.12

2022-09-30

0.13

2022-06-30

0.13

2022-03-31

0.14

2021-12-31

0.14

2021-09-30

0.16

2021-06-30

0.18

2021-03-31

0.23

2020-12-31

0.24

2020-09-30

0.27

2020-06-30

0.24

2020-03-31

0.06

2019-12-31

0.06

2019-09-30

0.07

2019-06-30

0.07

2019-03-31

0.08

2018-12-31

0.08

2018-09-30

0.09

2018-06-30

0.10

2018-03-31

0.11

2017-12-31

0.11

2017-09-30

0.12

2017-06-30

0.13

2017-03-31

0.15

2016-12-31

0.11

2016-09-30

0.09

2016-06-30

0.09

2016-03-31

0.10

2015-12-31

0.10

2015-09-30

0.12

2015-06-30

0.12

2015-03-31

0.16

2014-12-31

0.18

2014-09-30

0.22

2014-06-30

0.22

2014-03-31

0.24

2013-12-31

0.26

2013-09-30

0.29

2013-06-30

0.32

2013-03-31

0.33

2012-12-31

0.37

2012-09-30

0.56

2012-06-30

0.75

2012-03-31

0.87

2011-12-31

0.90

2011-09-30

0.37

2011-06-30

0.34

2011-03-31

0.31

2010-12-31

0.30

2010-09-30

0.46

2010-06-30

0.43

2010-03-31

0.41

2009-12-31

0.27

2009-09-30

0.15

2009-06-30

0.15

2009-03-31

0.00

2008-12-31

0.01

2008-09-30

0.27

2008-06-30

0.26

2008-03-31

0.43

2007-12-31

0.44

2007-09-30

1.32

2007-06-30

1.12

2007-03-31

1.02

2006-12-31

0.92

2006-09-30

3.20

2006-06-30

2.39

2006-03-31

1.95

2005-12-31

1.75

2005-09-30

1.47

2005-06-30

1.21

2005-03-31

1.08

2004-12-31

1.10

2004-09-30

1.12

2004-06-30

1.05

2004-03-31

0.98

2003-12-31

1.55

2003-09-30

1.34

2003-06-30

1.49

2003-03-31

1.21

2002-12-31

1.37

2002-09-30

1.11

2002-06-30

0.94

Debt to Equity Ratio: 0.09

REGN Debt to Equity Ratio

REGN Average Debt to Equity Ratio Chart

REGN Current vs Average Debt to Equity Ratio Chart

REGN Debt to Equity Ratio Metrics

REGN Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

REGN Debt to Equity Ratio History

Related Metrics